clinical trial · NCT04040322
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)
Civi Biopharma, Inc.·phase3·completed·n = 198
Raynaud's Phenomenon Secondary to Systemic SclerosisPlacebo IV infusionIloprost Injection, for intravenous use
brief summary
This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of iloprost on the frequency of and relief from symptomatic digital ischemic episodes in subjects with systemic sclerosis.
started
Oct 14, 2019
primary completion
Jun 9, 2021
completion
Jun 9, 2021
last updated
May 25, 2025
official title
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol